Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer: a Randomized Phase II Trial (DART)

NCT04641078 is registered in ClinicalTrials.gov with University Hospital, Ghent as lead sponsor.

NCT NCT04641078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04641078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer: a Randomized Phase II Trial (DART)
Lead sponsor
University Hospital, Ghent
Phase
Phase 2
Overall status
Unknown status
Start date
February 12, 2021
Completion date
February 12, 2026
Enrollment
124 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cancer, oligometastasis, prostate cancer, prostate cancer metastatic, prostate cancer recurrent